Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 1,760 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #1 Clear all

Conditions: Healthy
Interventions: sertraline 100 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Respiratory Tract Infection
Interventions: Formulation A, Formulation B, Formulation C, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more

Conditions: Cataract
Interventions: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Smoking Cessation
Interventions: NicVAX conjugate vaccine, Placebo; Biological
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 6 more

Conditions: Gaucher Disease
Interventions: eliglustat; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Relative Bioavailability, AUC, Cmax, Pharmacokinetics
Interventions: D1400147, D14000136, D14000137, Epanova®; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Dependence
Interventions: Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder
Interventions: ML-004 (IR)/(ER) tablet, ML-004 Placebo; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more

Conditions: Delayed Onset Muscle Soreness
Interventions: SST-0225, Placebo; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: South Miami, Florida • Springfield, Missouri

Conditions: Group B Streptococcus Infections
Interventions: Multivalent Group B streptococcus vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years to 40 Years
Enrollment: 1,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 26
States / cities: Mobile, Alabama • Phoenix, Arizona • Lancaster, California + 11 more

Conditions: Reversible Pulpitis, Dental Pulp Diseases
Interventions: NeoMTA, ProRoot MTA; Biological · Other
Lead sponsor: Texas A & M University Baylor College Of Dentistry; Other
Eligibility: 2 Years to 8 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hyperinsulinism-Hyperammonemia Syndrome
Interventions: Vitamin E; Dietary Supplement
Lead sponsor: Elizabeth A Rosenfeld; Other
Eligibility: 1 Year to 40 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Contraception
Interventions: Ethinylestradiol/Gestodene (BAY86-5016); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Tucson, Arizona • San Diego, California • Sandy Springs, Georgia + 3 more

Conditions: Thrombosis
Interventions: Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: MOR106, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Fountain Valley, California • Huntington Beach, California • Los Angeles, California + 11 more

Conditions: Healthy Volunteer
Interventions: Eliglustat, common blend proposed commercial formulation, Eliglustat, Phase 3 capsule formulation; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Acute Myocardial Infarction Type 1
Interventions: Deferiprone Tablets, Placebo; Drug
Lead sponsor: Rohan Dharmakumar; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Indianapolis, Indiana • Minneapolis, Minnesota

Conditions: Sleep, THC, Marijuana, Cannabis
Interventions: Dronabinol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY 987516); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Lucanix™, Placebo Comparator; Biological · Other
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: Bipolar I
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more

Conditions: Smallpox
Interventions: LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 651 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky

Conditions: Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Interventions: triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Taste Evaluation of Different Liquid Formulations With Eliglustat

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT

Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome

US Ovulation Inhibition Study in Obese Women

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007)

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Tetrahydrocannabinol (THC) and Sleep

Sun Protection Factor Assay (SPF Assay 18676)

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes